RecruitingPhase 3NCT04967989

Clarifying the Optimal Application of SLT Therapy Trial


Sponsor

University of Pittsburgh

Enrollment

790 participants

Start Date

Sep 7, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age 18 or older and in good health
  • Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):
  • High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes)
  • Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° \<15 dB (see figure on next page)
  • Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points \<15 dB or mean deviation -12.0 dB or better with 1 central 5° points \<15 dB (see figure on next page).
  • Each eye with BCVA 20/200 (UK 6/60) or better

Exclusion Criteria11

  • Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment)
  • Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure
  • Advanced POAG in either eye (worse than moderate POAG as defined above)
  • Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye
  • Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye
  • Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye
  • Contraindications to SLT or any other study intervention
  • Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye
  • Any intraocular surgical procedure within the past 6 months in either eye
  • Inability to attend all scheduled study visits
  • Pregnant or planning to become pregnant in the next 4 years

Interventions

PROCEDURELow Energy SLT

SLT performed at low energy

PROCEDUREStandard Energy SLT

SLT performed at standard energy


Locations(29)

Spokane Eye Clinical Research

Spokane, Washington, United States

Harvard Eye Associates

Laguna Hills, California, United States

Doheny Eye Center UCLA

Pasadena, California, United States

University of California, Davis

Sacramento, California, United States

University of California, San Francisco

San Francisco, California, United States

Mile High Eye Institute

Sheridan, Colorado, United States

Clear Vue Laser Eye Center

Lakeworth, Florida, United States

Northwestern Medical Group

Chicago, Illinois, United States

Chicago Arbor Eye Institute

Orland Park, Illinois, United States

Illinois Eye Center

Peoria, Illinois, United States

Wilmer Eye Institute Johns Hopkins

Baltimore, Maryland, United States

Massachusetts Eye and Ear

Boston, Massachusetts, United States

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States

Mark Latina, LLC

Reading, Massachusetts, United States

University of Michigan Kellogg Eye Center

Ann Arbor, Michigan, United States

Kresge Eye Institute Wayne State University

Detroit, Michigan, United States

New York Eye Surgery Associates

The Bronx, New York, United States

University Hospitals Eye Institute

Cleveland, Ohio, United States

Cleveland Clinic Cole Eye Institute

Cleveland, Ohio, United States

Devers Eye Institute

Portland, Oregon, United States

Eye Care Specialists

Kingston, Pennsylvania, United States

Scheie Eye Institute

Philadelphia, Pennsylvania, United States

Wills Eye Hospital

Philadelphia, Pennsylvania, United States

UPMC Eye Center

Pittsburgh, Pennsylvania, United States

Vanderbilt Eye Institute

Nashville, Tennessee, United States

Ophthalmology Associates

Fort Worth, Texas, United States

West Virginia University

Morgantown, West Virginia, United States

University of Wisconsin-Madison

Madison, Wisconsin, United States

Ocular Health Centre

Kitchener, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04967989


Related Trials